Here's what brokers are saying about the Allkem merger with Livent

Brokers have been crunching the numbers and have given their verdict on the Allkem-Livent merger.

| More on:
A group of executives sit in front of computer screens in a darkened room while a colleague stands giving a presentation with a share price graphic lit up on the wall

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The big news this week is that mergers and acquisitions (M&A) activity is heating up in the lithium industry with the proposed merger of Allkem Ltd (ASX: AKE) and Livent Corp (NYSE: LTHM).

The news went down well with investors on both sides of the Pacific Ocean, sending their shares hurtling higher.

But what about brokers? How have they responded to the Allkem-Livent merger? Let's find out.

Allkem merger creates a 'top 3 lithium producer'

Analysts at Goldman Sachs have responded positively to the news. The broker highlights that it will create a "top 3 lithium producer" globally if the transaction completes.

In addition, its analysts highlight that the combination of the two lithium miners will result in a stronger balance sheet that supports their growth opportunities. It said:

The merger would also imply a stronger/more defensive balance sheet to fund the proposed and possible growth pipeline, where management noted the current execution pipeline will continue without taking pause as both businesses are already fully funded to execute respective projects.

Goldman also suggested that the M&A activity may not stop at the Allkem merger, which will be music to the ears of ASX lithium shareholders. It commented:

On lithium sector M&A more broadly, as we have highlighted, those in a position for strategic consolidation with South American lithium brine producers (other developers/emerging operators) may also have synergies in these types of lithium projects, while global miners/commodities business likely remain interested in lithium assets.

Goldman has retained its buy rating. However, it hasn't changed its price target, which still sits at $12.90.

Brine processing techniques could be key

Morgans is also very positive on the Allkem merger with Livent. As well as the potential synergies, it highlights that the latter's advanced brine processing techniques could help driver a stronger performance from Allkem's assets. It said:

It is possible that the accelerated take up of different brine processing techniques at AKE's projects, that are used by LTHM, could unlock the large potential of those resources much faster than we and the market have allowed.

However, due to the jump in the Allkem share price yesterday, the broker has downgraded its shares to a hold rating with a $14.40 price target. It commented:

We reduce our rating to HOLD given the extremely strong share price reaction. We think the deal makes sense for AKE but there is limited fundamental upside given today's rally.

Though, it concedes that there's potential for a third-party to come in with a counteroffer that starts a bidding war. Keep an eye out for that!

Motley Fool contributor James Mickleboro has positions in Allkem. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Mergers & Acquisitions

a group of smart looking kids, wearing formal clothes and all with spectacles, sit in a line and smile charmingly.
Mergers & Acquisitions

Takeover bid launched for childcare operator

A takeover bid has been launched for an ASX-listed childcare operator, with its larger rival saying it makes sense to…

Read more »

a woman drawing image on wall of big fish about to eat a small fish
Mergers & Acquisitions

Macquarie names 16 potential ASX takeover targets

The broker thinks these shares could be taken over in the near term.

Read more »

A smiling young woman sits on a bridge in London checking her online shopping, indicating share price movement for ASX BNPL shares overseas.
Mergers & Acquisitions

Hansen just announced a new UK acquisition. So why is the share price falling?

The software provider expands its telco footprint with a UK buyout.

Read more »

Researchers and doctors with futuristic 3d hologram overlay for body anatomy or dna in hospital clinic.
Healthcare Shares

Medibank shares higher on $159m Better Medical acquisition

The private health insurance giant is making a big acquisition.

Read more »

An evening shot of a busy Times Square in New York.
Mergers & Acquisitions

ASX 300 stock tumbles on US expansion plans

An expansion into the United States isn't getting investors excited on Thursday.

Read more »

A woman sits at her home computer with baby on her lap, and the winning ticket in her hand.
Mergers & Acquisitions

Guess which ASX 300 share is jumping 9% on $110m acquisition

Let's see what is getting investors excited on Wednesday.

Read more »

A bearded man holds both arms up diagonally and points with his index fingers to the sky with a thrilled look on his face over these rising Tassal share price
Mergers & Acquisitions

ASX 300 stock jumps 23% to record high on 'transformational acquisition'

This share is heading to the moon on Tuesday. But why exactly?

Read more »

A man in a suit face palms at the downturn happening with shares today.
Mergers & Acquisitions

Guess which ASX 200 stock is crashing 13% on big news

This stock is being sold off on Thursday. But why?

Read more »